Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant

NCT01930162 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Single Umbilical Cord Blood Transplantation
Non-myeloablative Conditioning
Acute Lymphocytic Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia

Interventions

DRUG: HSC835

Sponsor

Novartis Pharmaceuticals